hydralazine has been researched along with Atherosclerosis in 9 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Atherosclerosis: A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aliskiren reduced the atherosclerotic plaque area and plaque neovessel density." | 1.40 | Renin inhibition reduces atherosclerotic plaque neovessel formation and regresses advanced atherosclerotic plaques. ( Cheng, XW; Hamrah, MS; Hao, CN; Hayashi, M; Hu, L; Kuzuya, M; Murohara, T; Shi, GP; Takeshita, K; Wu, H, 2014) |
| "Hydralazine pretreatment reversed DE-induced TF, tPA, TNF-α, and MMP-2 expression but not eNOS, RAGE, and HMGB-1." | 1.39 | Diesel exhaust induced pulmonary and cardiovascular impairment: the role of hypertension intervention. ( Andrews, D; Bass, V; Gilmour, MI; King, C; Kodavanti, UP; Krantz, QT; Ledbetter, AD; Nyska, A; Richards, JE; Schladweiler, MC; Thomas, RF, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kodavanti, UP | 1 |
| Thomas, RF | 1 |
| Ledbetter, AD | 1 |
| Schladweiler, MC | 1 |
| Bass, V | 1 |
| Krantz, QT | 1 |
| King, C | 1 |
| Nyska, A | 1 |
| Richards, JE | 1 |
| Andrews, D | 1 |
| Gilmour, MI | 1 |
| Wu, H | 1 |
| Cheng, XW | 1 |
| Hu, L | 1 |
| Hao, CN | 1 |
| Hayashi, M | 1 |
| Takeshita, K | 1 |
| Hamrah, MS | 1 |
| Shi, GP | 1 |
| Kuzuya, M | 1 |
| Murohara, T | 1 |
| Cassis, LA | 1 |
| Gupte, M | 1 |
| Thayer, S | 1 |
| Zhang, X | 1 |
| Charnigo, R | 1 |
| Howatt, DA | 1 |
| Rateri, DL | 1 |
| Daugherty, A | 1 |
| Bouguerne, B | 1 |
| Belkheiri, N | 1 |
| Bedos-Belval, F | 1 |
| Vindis, C | 2 |
| Uchida, K | 2 |
| Duran, H | 1 |
| Grazide, MH | 2 |
| Baltas, M | 1 |
| Salvayre, R | 2 |
| Nègre-Salvayre, A | 2 |
| Suganuma, E | 2 |
| Zuo, Y | 2 |
| Ayabe, N | 2 |
| Ma, J | 1 |
| Babaev, VR | 2 |
| Linton, MF | 2 |
| Fazio, S | 2 |
| Ichikawa, I | 2 |
| Fogo, AB | 2 |
| Kon, V | 2 |
| Escargueil-Blanc, I | 1 |
| Elbaz, M | 1 |
| Marcheix, B | 1 |
| Motojima, M | 1 |
| Ikeda, F | 1 |
| Azuma, K | 1 |
| Ogihara, T | 1 |
| Toyofuku, Y | 1 |
| Otsuka, A | 1 |
| Mita, T | 1 |
| Hirose, T | 1 |
| Tanaka, Y | 1 |
| Kawamori, R | 1 |
| Watada, H | 1 |
| Burcham, PC | 1 |
| Kaminskas, LM | 1 |
| Tan, D | 1 |
| Pyke, SM | 1 |
1 review available for hydralazine and Atherosclerosis
| Article | Year |
|---|---|
Carbonyl-scavenging drugs & protection against carbonyl stress-associated cell injury.
Topics: Acrolein; Alzheimer Disease; Animals; Atherosclerosis; Cell Death; Free Radical Scavengers; Humans; | 2008 |
8 other studies available for hydralazine and Atherosclerosis
| Article | Year |
|---|---|
Diesel exhaust induced pulmonary and cardiovascular impairment: the role of hypertension intervention.
Topics: Albumins; Animals; Atherosclerosis; Cardiovascular Diseases; Hydralazine; Hypertension; Lung Disease | 2013 |
Renin inhibition reduces atherosclerotic plaque neovessel formation and regresses advanced atherosclerotic plaques.
Topics: Amides; Angiotensin II; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Blood Pressure; Carrier | 2014 |
ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aortic Aneurysm, Abdominal; Apolipoproteins E; Ath | 2009 |
Antiatherogenic effect of bisvanillyl-hydralazone, a new hydralazine derivative with antioxidant, carbonyl scavenger, and antiapoptotic properties.
Topics: Animals; Antioxidants; Apoptosis; Atherosclerosis; Cell Adhesion; Cells, Cultured; Chelating Agents; | 2011 |
Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atherosclerosis; Choleste | 2006 |
Desensitization of platelet-derived growth factor receptor-beta by oxidized lipids in vascular cells and atherosclerotic lesions: prevention by aldehyde scavengers.
Topics: Aldehydes; Animals; Atherosclerosis; Cells, Cultured; DNA; Hydralazine; Hydrazines; Lipoproteins, LD | 2006 |
Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aortic Di | 2007 |
Angiotensin II type 1 receptor blocker reduces monocyte adhesion to endothelial cells in spontaneously hypertensive rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agen | 2007 |